ABIRATERONE相关论文
Until recently,docetaxel-based therapy represented the only therapy shown to prolong survival in patients with metastati......
Even in the era of novel targeted agents,switching to a second-line nonsteroidal antiandrogen (NSAA) is still widely use......
...
<strong>Background:</strong> According to the main prostate cancer guidelines, the response to treatment with abirateron......
雄激素剥夺疗法作为晚期前列腺癌的标准疗法迄今已有50余年。去势手术对多数患者起初有效,但最终会发展为去势抵抗性前列腺癌(CRPC......
阿比特龙是CYP17酶(17α-羟化酶/C17,20-裂解酶)的一种高选择性、不可逆抑制剂,主要通过全面抑制体内雄激素的合成用于转移性去势......
直到最近，基于 docetaxel 的治疗代表了显示出与变形阉割抵抗的前列腺癌症(mCRPC ) 在病人延长幸存的唯一的治疗。过去的年和一半被......
六不同治疗在与变形阉割抵抗的前列腺癌症(mCRPC ) 指向到病人的阶段 III 试用表明了改进幸存。为 mCRPC 的前线的治疗学的选择包......
在过去的 5 年，治疗和理解里变形阉割抵抗前列腺癌症(CRPC ) 戏剧性地改善了。我们阉割电阻的机制的理解允许到目标前列腺癌症的新......
目的分析和比较新疆地区醋酸阿比特龙联合泼尼松+雄激素剥夺治疗(ADT)和多西他赛联合泼尼松+雄激素剥夺治疗(ADT)治疗转移性去势抵......
前列腺癌是男性常见的恶性肿瘤。临床上常用的干扰雄激素的治疗药物是阿比特龙,但长期高剂量的阿比特龙治疗常导致患者前列腺肿瘤......
Three-weekly docetaxel plus prednisone is the standard first-line cytotoxic treatment for patients with metastatic castr......
Comparative analysis of the effectiveness of abiraterone before and after docetaxel in patients with
AIM:To study the efficacy and safety of abiraterone in patients with and without prior chemotherapy.METHODS:The database......
Most of the early prostate cancer has no obvious symptoms, but its malignancy metastasis will cause largely deaths. The ......
Future Directions in Metastatic Castration Resistant Prostate Cancer (mCRPC): Clinical Rationale and
Several recent studies in mCRPC have identified the mechanisms of tumoral growth after the disease becomes unresponsive ......
雄激素剥夺疗法作为晚期前列腺癌的标准疗法迄今已有50余年。去势手术对多数患者起初有效,但最终会发展为去势抵抗性前列腺癌（CRPC）,......
<正>背景:醋酸阿比特龙,被美国FDA批准作为化疗后的二线治疗药物用于转移性激素抵抗性前列腺癌(mCRPC),提高了总生存率。在此评估......
